Dr. Lu Xianping is the founder and now Chairman and CEO of one of China’s few truly innovative biotech companies, ChipScreen BioSciences Co. In this exciting interview, he shares the long journey towards the commercialization of their first cancer drug, Chidamide, launched in China in 2015, ad now awaiting market approval in Japan and the US; incisive comments on the state of the Chinese biopharma innovation environment; as well as his hopes to build ChipScreen into the next Genentech of China!
Dr. Lu, could you please introduce ChipScreen to our international audience?
"There are now so many overseas Chinese returning to China to establish new companies that I have confidence China will make some huge breakthroughs in this industry in the next ten years."
